benchling

In this episode, Hannah Rosen speaks with Glenwood Barbee, M.B.A., Product Marketer at Benchling. Glenwood discusses Benchling Connect – a platform designed to accelerate connectivity and automation in laboratory settings.

Glenwood highlights Benchling's mission to revolutionize biotechnology by bringing modern software to modern science.
The conversation delves into the challenges of data standardization in life sciences. Glenwood outlines customers' primary pain points: 

• Disconnected instruments
• Inaccessible data due to proprietary formats
• Fragmented analytics leading to data lineage issues

Overall, the episode sheds light on the critical role of data standardization and automation in driving scientific progress, with Benchling at the forefront of innovation in the life sciences industry.

Full Transcript Available on Buzzsprout

Our Sponsor for this Episode
Benchling creates the software that powers the biotechnology industry. More than 200,000 scientists at over 1,200 companies globally —  from cutting-edge start-ups to 20+ of the 50 largest global biopharma — rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. Benchling is on a mission to accelerate scientific progress through advanced software that's purpose-built for biology.

To learn more,  visit: Benchling.com

Stay connected with SLAS

• Online at www.slas.org
• Facebook
• Twitter @SLAS_Org
• LinkedIn
• Instagram @slas_org
• YouTube

About SLAS
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building. 

Upcoming SLAS Events:

SLAS Building Biology in 3D Symposium

• April 16-17, 2024
• Jupiter, FL, USA

SLAS Europe 2024 Conference and Exhibition

• May 27-29, 2024
• Barcelona, Spain

View the full events calendar

Benchling's success didn't come overnight. Some ten years after its founding, the company is worth more than $6 billion, and the founder sees the company going public in the future. The company's future looks like its past: talking to customers and building for power users.

Benchling's CEO and co-founder, Sajith Wickramasekara, recently spoke at a TechCrunch Live event along with one of its early investors, Miles Grimshaw, general partner at Benchmark. Together, the two explained Benchling's early strategy that tapped a small entry market, which eventually led to widespread adoption.

As Wickramasekara explained, early funding was hard to secure. It was 2012, and Benchling sat alone between SaaS companies and biotech. "Every software investor thought what we were doing was small and unimportant," Wickramasekara said, adding later, "and then we went to science investors, and every science investor understood the challenges of R&D, but they didn't understand software; they invested in drugs."

TechCrunch Live records weekly on Wednesdays at 11:30 a.m. PDT/2:30 p.m. EDT. Join us!